The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
Open accessAbstract
A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. There is evidence that lasting changes in the personality feature of "openness" occur in response to hallucinogens, and that this may potentially act as a therapeutic mechanism of change. The present study investigated whether heightened Openness and decreased Neuroticism served as a mechanism of change within a randomized trial of MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD. The Clinician-Administered PTSD Scale (CAPS) Global Scores and NEO PI-R Personality Inventory (NEO) Openness and Neuroticism Scales served as outcome measures. Results indicated that changes in Openness but not Neuroticism played a moderating role in the relationship between reduced PTSD symptoms and MDMA treatment. Following MDMA-assisted psychotherapy, increased Openness and decreased Neuroticism when comparing baseline personality traits with long-term follow-up traits also were found. These preliminary findings suggest that the effect of MDMA-assisted psychotherapy extends beyond specific PTSD symptomatology and fundamentally alters personality structure, resulting in long-term persisting personality change. Results are discussed in terms of possible mechanisms of psychotherapeutic change.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies using MDMA with individual psychotherapy have yielded significant improvements in PTSD symptoms, and other outcomes such as increased openness to experience, posttraumatic growth, and improvement in comorbid conditions (Gorman et al., 2020; Mithoefer et al., 2019, 2018; Wagner et al., 2017).”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Wagner et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDMA has been shown to improve psychological flexibility, reduce fear of negative evaluation, and enhance self-reflection (89, 134–136).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [134]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
(1992) · Cited by 5,228
Complex PTSD: A syndrome in survivors of prolonged and repeated trauma
Herman, J. L. (1992) · Journal of Traumatic Stress · doi:10.1002/jts.2490050305 · Cited by 2,609 · cited 3×
“psychological fragmentation, loss of a sense of safety, trust, and self-worth, loss of a coherent sense of self) (Herman, 1992).”
BackgroundClinician-administered PTSD scale: A review of the first ten years of research
Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001) · Depression and Anxiety · doi:10.1002/da.1029 · Cited by 1,903
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“In modern research, Griffiths and colleagues studied the effects of oral psilocybin on psilocybin-naive normal volunteers (Griffiths et al., 2006, 2008).”
The Revised NEO Personality Inventory (NEO-PI-R)
Costa, P. T., & McCrae, R. R. (2008) · SAGE Publications Ltd eBooks · doi:10.4135/9781849200479.n9 · Cited by 1,569
A clinician rating scale for assessing current and lifetime PTSD. The CAPS-1
Blake, D. D., Weathers, F. W., Nagy, L., Kaloupek, D. G., Klauminzer, G. W., Charney, D. S., & Keane, T. M. (1990) · Behavior Therapy · Cited by 1,123
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Self-citation
Research works printed but not linked: 6
- Blake DD, 1990, Behavior Therapy, 13, 187
- Costa PT, 1992, NEO PI-R Professional Manual
- First M, 1997, Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II): Interview and Questionnaire
- First MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 Revision)
- 10.1038/sj.npp.1395197 · DOI · Paper page
- World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
Cited by
Sorted by citations
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439
Self-citationReviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Feduccia, A. A., & Mithoefer, M. C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.003 · Cited by 217
Self-citationTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault‐Phillips, S., Nijdam, M. J., McFARLANE, A. C., & Vermetten, E. H. G. J. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 251
Lyons, T., & Carhart-Harris, R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117748902 · Cited by 201
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00650 · Cited by 172
Self-citationByock, I. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2017.0684 · Cited by 161
Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05548-2 · Cited by 159
Self-citationRetractedYao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
The Cambridge Handbook of Personality Psychology
(2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822 · Cited by 148
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Erritzøe, D., Smith, J., Fisher, P. M., Carhart-Harris, R. L., Frøkjær, V. G., & Knudsen, G. M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827891 · Cited by 97
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06083-y · Cited by 88
Monson, C. M., Wagner, A. C., Mithoefer, A. T., Liebman, R. E., Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Doblin, R., & Mithoefer, M. C. (2020) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1840123 · Cited by 96
“…using MDMA with individual psychotherapy have yielded significant improvements in PTSD symptoms, and other outcomes such as increased openness to experience, posttraumatic growth, and improvement in comorbid conditions (Gorman et al., 2020; Mithoefer et al., 2019, 2018; Wagner et al., 2017).”
Self-citationTemperament and brain networks of attention
Posner, M. I., & Rothbart, M. K. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0254 · Cited by 95
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 96
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020) · Chronic Stress · doi:10.1177/2470547020939564 · Cited by 87
Replication and extension of a model predicting response to psilocybin
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. M., & Elliott, M. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05279-z · Cited by 83
Effects of MDMA on attention to positive social cues and pleasantness of affective touch
Bershad, A. K., Mayo, L. M., Hedger, K. V., McGlone, F. P., Walker, S. C., & de Wit, H. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0402-z · Cited by 76
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.710004 · Cited by 79
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998322 · Cited by 57
Methylenedioxymethamphetamine (MDMA) in Psychiatry
Schenk, S., & Newcombe, D. A. L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000962 · Cited by 53
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., Yazar‐Klosinski, B., Emerson, A., & Feduccia, A. A. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22479 · Cited by 44
Self-citationStauffer, C. S., Brown, M. R., Adams, D., Cassity, M., & Sevelius, J. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.932605 · Cited by 45
Oeri, H. E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120920420 · Cited by 43
DePierro, J. M., Lepow, L., Feder, A., & Yehuda, R. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.009 · Cited by 41
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
Sottile, R., & Vida, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.991753 · Cited by 41
MDMA and memory, addiction, and depression: dose-effect analysis
Pantoni, M. M., Kim, J. L., Alstyne, K. R. V., & Anagnostaras, S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06086-9 · Cited by 41
Stojek, M. M., McSweeney, L. B., & Rauch, S. A. M. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00281 · Cited by 37
Ben‐Eliyahu, A., & Zeidner, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.041 · Cited by 33
Torre, J. T. L., Mahammadli, M., Faber, S. C., Greenway, K. T., & Williams, M. T. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-023-01149-0 · Cited by 32
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1415755 · Cited by 31
Whitfield, H. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727572 · Cited by 32
Lyubomirsky, S. (2022) · Perspectives on Psychological Science · doi:10.1177/17456916211055369 · Cited by 34
Ching, T. H. W., Williams, M. T., Wang, J. B., Jerome, L., Yazar‐Klosinski, B., Emerson, A., & Doblin, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104052 · Cited by 29
Self-citationOptimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 31
DeYoung, C. G., & Blain, S. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.026 · Cited by 34
Luoma, J. B., Shahar, B., Lear, M. K., Pilecki, B. C., & Wagner, A. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2824 · Cited by 29
O’Donnell, K. C., Alpert, M., Okano, L., Nicholas, C. R. N., Thomas, C., Poulter, B., Mithoefer, A. T., Mithoefer, M. C., & Marcela Ot’alora, G. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1427531 · Cited by 26
Self-citationHavenith, M. N., Leidenberger, M., Brasanac, J., Corvacho, M., Figueiredo, I., Schwarz, L., Uthaug, M. V., Rakusa, S., Bernardic, M., Vasquez-Mock, L., et al. (2025) · Communications Psychology · doi:10.1038/s44271-025-00247-0 · Cited by 30
Feduccia, A. A., Jerome, L., Yazar‐Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021013 · Cited by 24
Self-citationReisenzein, R., Hildebrandt, A., & Weber, H. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.009 · Cited by 26
Psychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 32
Mai, J., Wu, Y., Ling, Z., Lin, L., & Xinying, S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.835909 · Cited by 26
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 25
Marchetta, E., Mancini, G. F., Morena, M., & Campolongo, P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221207162750 · Cited by 17
Riaz, K., Suneel, S., Malik, M. H. B. A., Kashif, T., Ullah, I., Waris, A., Nicola, M. D., Mazza, M., Sani, G., Martinotti, G., et al. (2023) · Diseases · doi:10.3390/diseases11040159 · Cited by 19
Dale, R. M., Bryant, K. A., Finnegan, N., Cromer, K., Thompson, N. R., Altinay, M. I., & Anand, A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.010 · Cited by 20
MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail
Bedi, G., Cotton, S. M., Guerin, A. A., & Jackson, H. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221127186 · Cited by 18
Robinson, M. D., & Sedikides, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.031 · Cited by 18
MDMA-assisted psychotherapy for borderline personality disorder
Traynor, J. M., Roberts, D. E., Ross, S., Zeifman, R., & Choi-Kain, L. (2022) · Focus · doi:10.1176/appi.focus.20220056 · Cited by 15
Sippel, L. M., Hamblen, J. L., Kelmendi, B., Alpert, J. E., Carpenter, L. L., Grzenda, A. L., Kraguljac, N. V., McDonald, W. M., Rodríguez, C. I., Widge, A. S., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230950 · Cited by 15
The Five-Factor Model of Personality: Consensus and Controversy
McCrae, R. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.013 · Cited by 20
Couple Therapy With MDMA—Proposed Pathways of Action
Wagner, A. C. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.733456 · Cited by 16
Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol
Lear, M. K., Smith, S. M., Pilecki, B. C., Stauffer, C. S., & Luoma, J. B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1083354 · Cited by 15
Sensitization to the Prosocial Effects of 3,4-Methylenedioxymethamphetamine (MDMA)
Curry, D. W., Berro, L. F., Belkoff, A. R., Sulima, A., Rice, K. C., & Howell, L. L. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.017 · Cited by 13
Elfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 16
A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Lewis, B. R., & Byrne, K. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20220088 · Cited by 14
Schmid, Y., & Bershad, A. K. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.001 · Cited by 15
Elmer, T., Vannoy, T. K., Studerus, E., & Lyubomirsky, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-51355-6 · Cited by 12
van der Gronde, T., Los, L., Herremans, A. H. J., Oosting, R. S., Zorzanelli, R., & Pieters, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00412 · Cited by 12
Evolutionary Personality Psychology
Lewis, D. M. G., Al-Shawaf, L., & Buss, D. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.022 · Cited by 11
Christie, D., Yazar‐Klosinski, B., Nosova, E., Kryskow, P., Siu, W., Lessor, D., & Argento, E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.939302 · Cited by 13
Self-citationChing, T. H. W., Williams, M. T., Reed, S. J., Kisicki, M. D., Wang, J. B., Yazar‐Klosinski, B., Emerson, A., & Doblin, R. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221076993 · Cited by 10
Self-citationDevelopment of Personality across the Life Span
Atherton, O. E., Donnellan, M. B., & Robins, R. W. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.017 · Cited by 15
Cross-validation of the ego dissolution scale: implications for studying psychedelics
Lynn, S. J., McDonald, C. W., Sleight, F. G., & Mattson, R. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267611 · Cited by 10
Approach–Avoidance Theories of Personality
Corr, P. J., & Krupıć, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.025 · Cited by 12
Bhagavan, C., Glue, P., Evans, W., Reynolds, L., Turner, T., King, C., Russell, B. R., Morunga, E., Mills, J. L., Layton, G., et al. (2024) · Trials · doi:10.1186/s13063-024-08174-x · Cited by 10
Ecstasy tablets: Rapid identification and determination of enantiomeric excess of MDMA
Fagan, P., Spálovská, D., Kuchař, M., Černohorský, T., Komorousová, L., Kocourková, L., & Setnička, V. (2021) · Forensic Chemistry · doi:10.1016/j.forc.2021.100381 · Cited by 8
Caprara, G. V., & Vecchione, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.038 · Cited by 9
Fagan, P., Spálovská, D., Jurok, R., Kuchař, M., Schrenková, V., & Setnička, V. (2021) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2021.103255 · Cited by 8
Conceptual and Historical Perspectives
Cloninger, S. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.004 · Cited by 8
Ethical considerations for psychedelic-assisted therapy in military clinical settings
Hoener, S., Wolfgang, A. S., Nissan, D. A., & Howe, E. G. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2023-108943 · Cited by 8
Albert, A. E., & Back, A. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1529427 · Cited by 6
Psychedelic-assisted Psychotherapy in 3-D: Acceptance, Connectedness, and Defensiveness
Fischman, L. G. (2023) · Neuropsychoanalysis · doi:10.1080/15294145.2023.2255991 · Cited by 6
The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD
Maples‐Keller, J. L., Dunlop, B. W., & ROTHBAUM, B. O. (2024) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2024.101400 · Cited by 7
Personality, Preferences and Socioeconomic Behavior
Ferguson, E., Zhao, K., & Smillie, L. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.044 · Cited by 6
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021012 · Cited by 9
User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample
Elsey, J. W. B., Wuestman, V. A. F., & Fieten, A. (2023) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2023.2284643 · Cited by 6
Temperament and Brain Networks of Attention
Rothbart, M. K., Posner, M. I., & Sheese, B. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.016 · Cited by 8
Biesanz, J. C., & Wallace, J. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.006 · Cited by 7
Perivoliotis, D., Knopp, K. C., Remick, S., Kaigle, A., Stauffer, C. S., Khalifian, C. E., Wachsman, T. R., Chargin, B. E., Bismark, A. W., Alam, A., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1433999 · Cited by 6
Stanicic, F., Zah, V., Grbic, D., & de Angelo, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313569 · Cited by 5
Personality in Clinical Psychology
Widiger, T. A., & McCabe, G. A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.042 · Cited by 5
States and Situations, Traits and Environments
Asendorpf, J. B., & Rauthmann, J. F. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108264822.007 · Cited by 10
Combinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 6
Fischman, L. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1469559 · Cited by 7
Luoma, J. B., Lear, M. K., Yi, K., & Pilecki, B. C. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.02.002 · Cited by 5
The role of Ecstasy (MDMA) in managing intimacy and conflict in stable relationships
Kostick, K. M., & Schensul, J. J. (2018) · Culture Health & Sexuality · doi:10.1080/13691058.2018.1475682 · Cited by 4
Altman, B. R., Earleywine, M., & Leo, J. A. D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2020382 · Cited by 4
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha, M., Marcinowicz, P., Komarnicki, J., Tobiaszewska, M., Dębowska, W., Dębowska, M. D., & Szulc, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1398859 · Cited by 8
Demirel, G., Güzel, E., Creighton, C. J., Öztürk, Y. E., Küçük, C., Aslıyüksek, H., & Yurdun, T. (2019) · PubMed Central · doi:10.22037/ijpr.2019.15097.12874 · Cited by 4
Ramaekers, J. G., Kuypers, K. P. C., & Vollenweider, F. X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03602-7 · Cited by 3
Metadata
- Authors
- Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T., MacAulay, R. K., Jerome, L., Yazar-Klosinski, B., & Doblin, R.
- Affiliations
- Medical University of South Carolina (US)
- Private Practice, Mount Pleasant, USA
- University of Maine (US)
- MAPS Public Benefit Corp (MPBC), Santa Cruz, USA
- Multidisciplinary Association for Psychedelic Studies, Santa Cruz, USA
- Multidisciplinary Association for Psychedelic Studies (US)
- Corresponding author
- Wagner, Mark T
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-06-21
- Volume
- 31
- Issue
- 8
- Pages
- 967-974
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC5544120
- OpenAlex
- W2716623847
- Cited by
- 160
- References
- 51
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 21 · 2023: 14 · 2022: 18 · 2021: 11 · 2020: 49 · 2019: 10 · 2018: 10 · 2017: 4
- FWCI
- 24.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, treatment-resistant PTSD, personality change, openness to experience, neuroticism, mechanisms of change, hallucinogens, personality traits
- MeSH terms
- Neuroticism, Adult, Combined Modality Therapy, Female, Hallucinogens, Humans, Male, Personality Inventory, Psychotherapy, Stress Disorders, Post-Traumatic, Treatment Outcome, N-Methyl-3,4-methylenedioxyamphetamine, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
